ReviewRadiology2018
Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.
Review in Radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06551805 (Clinical Research Protocol of Ferumoxytol for Magnetic Resonance Enhancement Imaging in Patients With Atherosclerosis.), which is not on this map. Cited by 115 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Research Protocol of Ferumoxytol for Magnetic Resonance Enhancement Imaging in Patients With Atherosclerosis.
Who cites it
115 citing papers in PubMed, 2 syntheses or guidelines pooled it, 274 citations in OpenAlex.
- Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity.Journal of magnetic resonance imaging : JMRI · 2025Pooled it
- Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.Annals of internal medicine · 2020Pooled it
- Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial.European radiology · 2021Trial
- Gadopiclenol Breast MRI With Half Standard Gadolinium Dose Maintains High Parenchymal Contrast in Intraindividual Comparison.Investigative radiology · 2026Article
- Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment.Clinical pharmacokinetics · 2026Article
- Effect of liver fibrosis on gadolinium retention from gadodiamide, gadobutrol, and gadoxetate disodium in rats.Japanese journal of radiology · 2026Article
- Relaxivity comparison of Gadoteric acid and Gadopiclenol using clinical and reference MRI sequences at 1.5 T.Magma (New York, N.Y.) · 2026Article
- Artificial intelligence-amplified contrast enhancement in brain magnetic resonance imaging for improving image quality and lesion visualization: a prospective pilot study.Quantitative imaging in medicine and surgery · 2026Article
- Designing Water-Soluble Macromolecules for Biomedical Use: PEG Chains versus Amino AcidsA Case Study in MRI Contrast Agents.ACS polymers Au · 2026Article
- Repeated gadolinium-based contrast agent exposure increases depression-like behavior in rats.Japanese journal of radiology · 2026Article
- Downstream evaluation of synthetic AI-generated TFrontiers in radiology · 2026Article
- Pharmacokinetics, Excretion, and Organ Distribution of the Novel Gadolinium-Based MRI Contrast Agent Gadoquatrane in Female Cynomolgus Monkeys.Investigative radiology · 2025Article
- Gadopiclenol Enables Reduced Gadolinium Dose While Maintaining Quality of Pulmonary Arterial Enhancement for Pulmonary MRA: An Opportunity for Improved Safety and Sustainability.Investigative radiology · 2025Article
- Multicore SPION Clustering within Poly(amino acid) Corrals for Enhanced MRI Contrast and Drug Release.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- GlioSurv: interpretable transformer for multimodal, individualized survival prediction in diffuse glioma.NPJ digital medicine · 2025Article
- Feasibility of a reduced gadolinium dose protocol for MRI-guided radiotherapy in glioblastoma.Acta oncologica (Stockholm, Sweden) · 2025Article
- Hypersensitivity Reactions to Gadolinium-Based Contrast Agents: Update From an Allergist's Point of View.Clinical and translational allergy · 2025Review
- Ultra-high temporal resolution 4D angiography using arterial spin labeling with subspace reconstruction.Magnetic resonance in medicine · 2025Article
- Diffusion-weighted arterial spin labeling MRI to investigate mannitol-induced blood brain barrier disruption.Magnetic resonance imaging · 2025Article
- Contrast Agents in Breast MRI: State of the Art and Future Perspectives.Biomedicines · 2025Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians to obtain crucial life-saving medical information that often cannot be obtained with other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile; however, recent information has raised new concerns over the safety of GBCAs. Mounting evidence has shown there is long-term retention of gadolinium in human tissues. Further, a small subset of patients have attributed a constellation of symptoms to GBCA exposure, although the association of these symptoms with GBCA administration or gadolinium retention has not been proven by scientific investigation. Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. In February 2018, an international meeting was held in Bethesda, Md, at the National Institutes of Health to discuss the current literature and knowledge gaps about gadolinium retention, to prioritize future research initiatives to better understand this phenomenon, and to foster collaborative standardized studies. The greatest priorities are to determine (a) if gadolinium retention adversely affects the function of human tissues, (b) if retention is causally associated with short- or long-term clinical manifestations of disease, and (c) if vulnerable populations, such as children, are at greater risk for experiencing clinical disease. The purpose of the research roadmap is to highlight important information that is not known and to identify and prioritize needed research. ©RSNA, 2018 Online supplemental material is available for this article .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.